Skip to main content

Table 1 Patient characteristics

From: Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

Characteristics

Number (n)

Percentage (%)

Gender

  

   Male

15

68.2

   Female

7

31.8

Stage

  

   IIIA

11

50

   IIIB

11

50

KPS

  

   70

4

18.2

   80

5

22.7

   90

12

54.5

   100

1

4.5

Histology

  

   Adenocarcinoma

6

27.3

   Squamous cell carcinoma

12

54.5

   Adenosquamous cell carcinoma

1

4.5

   Unclassified

3

13.6

ICT

  

   Yes

18

81.8

   No

4

18.2

ICT Regimens

  

   PE

4

22.2

   NP or NC

6

33.3

   GP

3

16.7

   INC

2

11.1

   TC

2

11.1

   INC + TC

1

5.6

Number of ICT Cycles

  

   2–3

11

61.1

   ≥4

7

38.9

Response to ICT

  

   PR

9

50

   SD

5

27.8

   PD

4

22.2

  1. ICT: Induction Chemotherapy, PE: Cisplatin-Etoposide, NP: Vinorelbine-Cisplatin, NC: Vinorelbine-Carboplatin, GP: Gemcitabine-Cisplatin, INC: Ifosfamide-Navelbine-Carboplatin, TC: Paclitaxel-Carboplatin, PR: Partial Response, SD: Stable Disease, PD: Progressive Disease